MONOCLONAL ANTIBODY FOR RECURRENT MALIGNANT BRAIN TUMORS

针对复发性恶性脑肿瘤的单克隆抗体

• 批准号: 3864822
• 负责人: BEVERLY LANGE
• 金额: --
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3864822
• 关键词: brain neoplasms; cell mediated cytotoxicity; dosage; epidermal growth factor; glioma; growth factor receptors; human subject; monoclonal antibody; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer relapse /recurrence; pediatric neoplasm /cancer

In a phase trial, pts with recurrent CNS primitive neuroectodermal tumors or recurrent gliomas receive I131 radiolabelled receptor (EGFr Mab-425). If nuclear scans show uptake of EGFr Mab-425 in the tumor, patients then receive the cytotoxic antibody. Three pts will be tested at each dose of cytotoxic antibody.

在一个阶段试验中，复发的CNS原始神经外胚层患者 肿瘤或复发的胶质瘤接受放射性核素标记受体(EGFR) MAB-425)。如果核扫描显示肿瘤内摄取了EGFR Mab-425， 然后，患者接受细胞毒性抗体。将对三个分数进行测试 在每一剂量的细胞毒抗体。